Phenobarbital Sodium Injection recalled for manufacturing sterility defect
Vitae Enim Vitae Scientific, Inc. is recalling Phenobarbital Sodium Injection nationwide due to deviations from Current Good Manufacturing Practices (CGMP) that raise concerns about product sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall without reported illnesses or injuries, based on manufacturing deviations affecting sterility of an injectable drug. The hazard is theoretical rather than confirmed, meeting the High severity threshold for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Vitae Enim Vitae Scientific, Inc. is recalling Phenobarbital Sodium Injection, USP, 130 mg/mL. The recalled product consists of 18,531 boxes containing 25 x 1 mL vials (NDC 42494-416-25) and 4,492 boxes containing 3 x 1 mL vials (NDC 42494-416-03), manufactured for Cameron Pharmaceuticals, LLC. Multiple lots are affected with expiration dates ranging from March 2022 through August 2024.
The product is being recalled due to deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile. Phenobarbital Sodium Injection is a prescription injectable medication, and lack of assurance of sterility poses a potential risk to patients.
The recalled product was distributed nationwide in the U.S.A. If you have received this product, do not use it. Contact your healthcare provider or pharmacy for guidance. Pharmacies and healthcare facilities should quarantine any affected stock and contact the manufacturer or distributor for return instructions.
The recalled product
- Product
- PHENOBARBITAL SODIUM (PHENOBARBITAL SODIUM)
- Brand
- PHENOBARBITAL SODIUM
- Manufacturer
- Vitae Enim Vitae Scientific, Inc.
- Category
- Drug — Injectable
- Hazard
- sterility-defect
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # a) 20VPSI011
- Exp. 4/30/2022
- 20VPSI014
- Exp. 5/31/2022
- 20VPSI020
- 20VPSI022
- 20VPSI023
- Exp. 7/31/2022
- 21VPSI007
- Exp. 3/31/2023
- 21VPSI013
- Exp. 5/31/2023
- 21VPSI027
- Exp. 6/30/2023
- 21VPSI039
- Exp. 8/31/2023
- 21VPSI042
- Exp. 10/31/2023
- 21VPSI049
- Exp. 11/30/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · PHENOBARBITAL SODIUM
- HighPhenobarbital Sodium Injection Recalled for Sterility Assurance Deviations
FDA (Drugs) · 2022-04-13
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27